© 2023 BioMarin. All rights reserved.

Our Motivation | July 21, 2023

Raising a Child with Hemophilia: BioMarin Employee Jess Klass Shares Her Story

After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.

Science | June 29, 2023

FDA Approves BioMarin’s Gene Therapy for a Genetic Bleeding Disorder

We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]

A Message from the Chairman and CEO

Dear Stockholder of BioMarin: In 2022, BioMarin achieved record revenue and pivoted to GAAP profitability, making it a truly transformational year for the company and laying the foundation for long-term growth. The global launch of VOXZOGO for children with achondroplasia helped drive that revenue growth. We believe conditional European approval of our gene therapy for […]

Read More read more
Our People | February 27, 2023

BioMarin Pioneer Honored through New Building Name and Book Launch

“BioMarin stands on the precipice of a gene therapy revolution, and this is a dream come true,” said Robert A. Baffi, Ph.D., retired president of Global Manufacturing and Technical Operations, at a ceremony announcing the renaming of our gene therapy manufacturing facility in his honor and the launch of his new book on how to […]

Our People, Science | December 8, 2022

At the Intersection of Science and Art

It should not come as a surprise to anyone that art and science are siblings. Faced with a lump of clay, a potter has a world of infinite possibility at their beck and call. Every revolution of the potter’s wheel is the beginning of a journey, of an experiment. With much trial and error, with […]

Our Company | December 5, 2022

Enduring Purpose, Expanding Reach

As we reflect on the progress of the last quarter century, we take this opportunity to also look forward to what’s next for BioMarin. In our continued pursuit to maximize impact for patients, we continue to ask ourselves: what more can we do? The outcome of this ongoing self-assessment has helped bring clarity to how we can best deliver on our purpose – to transform lives through genetic discovery.